Cross Cultural Workforce Engagement Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India.

Slides:



Advertisements
Similar presentations
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Advertisements

1 Agenda Business Overview Operational & Financial Performance - ICICI Limited Asset Composition and Quality - ICICI Limited Capital and Shareholders -
European Skills for the 21 st Century Presentation at AGORA Thessaloniki XXVI Conference: “Building A European VET Area”, th April 2007 Professor.
Exporting For Growth Brian Cooper International Trade Adviser Advanced Engineering
Global Dynamism Index (GDI) 2013 summary report Model developed by the Economist Intelligence Unit (EIU)
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
Standard Register Fourth Quarter and Full Year 2007 Conference Call February 22, 2008.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
The Challenges from India in the Global Generic Market Place Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories.
1 FDI Confidence Index ® 2003 FDI Confidence Index ® The Global Business Policy Council Press Slides September 2003.
The Role of Generics in Reducing the Cost of Healthcare Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited,
IT Outsourcing Opportunities in US and China
Hale & Tempest Understanding the Strategies Big Pharma are Developing to win in the Global Generics Market Dr. Brian W Tempest Istanbul,
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul,
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Shortage of Natural Resources The Scientific Innovative Power coming from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
© economiesuisse,, Challenges for Switzerland‘s Foreign Trade Policy Gerold Bührer, Chairman 36th Annual General Meeting 2010 ARAB-SWISS CHAMBER OF COMMERCE.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Mumbai – September.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
The New Economic Landscape Brian W Tempest CEO & Managing Director Ranbaxy Laboratories Limited, India The Pharmaceutical Industry in the 21 st Century.
The intra and inter-firm geography of EMNCs: India’s pharmaceuticals Rory Horner Clark University Graduate School of Geography Presentation for ‘Emerging.
Hale & Tempest Distribution, OTC & CRAMS Chesapeake Dr. Brian W Tempest UK March 2014.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Hale & Tempest Moving Beyond the Commodity Market: What Future is there in added Value Generics, Niche Products and Biosimilars? Dr. Brian W Tempest
Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest CpHI Ramada Hotel, Berlin, Germany 11 September 2013.
Region 10 Asia-Pacific IEEE R10 Meeting, Ahmedabad, 3-4 February 2008 Janina Mazierska IEEE Asia Pacific Director
Partners in Globalisation UK Trade & Investment British Business Group in Mumbai & Pune Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Zurich – October.
Asia’s Quest for World Leadership Talk given by Rodolfo C. Severino, Head, ASEAN Studies Centre, Institute of Southeast Asian Studies, at the 7 th Asia.
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest CII Pharma Summit Mumbai Thursday November 1 st.
Hale & Tempest India UKIBC Briefing Dr. Brian W Tempest UK India Business Council Manchester 10 March 2011.
New Global Economic Powers and the Environment Dr. Peter Bosshard Policy Director, International Rivers Beijing, April 18, 2011.
Sustaining America’s High Tech Future Innovation and STEM Competitiveness Presented by Marjorie Bynum Vice President, Globally Competitive Workforce The.
Advantages of India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Clinical Trials.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Manila – 29.
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest MAPE Fund Managers Conference.
Hale & Tempest A View from India Dr. Brian W Tempest Opinion Formers’ Conference on Intellectual Property for Better Health Wellcome.
The Atlas of Ideas : Mapping the new geography of science Sir David King Chief Scientific Adviser to HM Government 17 January 2006.
New Perspectives on Engineering Education and the Job Market: Challenges, Opportunities Dr. Samir AL-Baiyat Dean, College of Engineering Sciences, King.
INTERNATIONAL TRADE LECTURE 1: The World of International Economics.
India – a growing player Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited Frankfurt – 15 th March’06.
Investor Presentation1 Creating Lasting Value Investor Presentation June 2009.
Fortis Healthcare Limited Earnings Call – Q2 – FY09.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
NEW CARDS: IMPERIALISM 59.IMPERIALISM 60.SEPOY MUTINY 61.BOER WAR 62.OPIUM WAR 63.TREATY OF NANJING 64.SPHERE OF INFLUENCE 65.TAIPING REBELLION 66.SUN.
Hale & Tempest Indian Drug Discovery Dr. Brian W Tempest Asia Pacific Technology Network Tuesday 3 April 2012.
Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul,
Hale & Tempest Doing Business in Russia - the View from Overseas Dr. Brian W Tempest CpHI St Petersburg, Russia 17 April 2014.
Partnering Opportunities in India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Bio-Partnering.
Succeeding in Japan Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Japan Initiative.
Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest Shanghai, China 18 November 2011.
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Hale & Tempest Consultation of Experts to discuss the WHO role in facilitating access to quality, affordable biotherapeutics (monoclonal antibodies & biosimilars.
Internationalisation Strategy Refresh Baseline data analysis Research Team Spring 2016.
“Card Diversity and Novel Prepaid Card Applications Spur Growth in the Prepaid Cards Market” © Global Industry Analysts, Inc., 6150 Hellyer Ave., San Jose,
Hale & Tempest Patents & Health Dr. Brian W Tempest Seminar on the Relationship between Patent Systems and the Availability of Medicines.
Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.
Bologna Process – ICT industry expectations
Issues for the future University
The intra and inter-firm geography of EMNCs: India’s pharmaceuticals
Chemical Industry in Europe – Trends
Internationalisation of higher education in the UK
Realities, Challenges, and Promises - Promoting the Next Generation of English Teachers in China Jun Liu May 18, 2007 Beijing, China.
Presentation transcript:

Cross Cultural Workforce Engagement Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Human Resources Council – India Conference Board 16 th February 2007, Taj Mahal Hotel, Delhi

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Disclaimer

Economic Background Global Major Issues - USA on the verge of a military defeat -Iran and N.Korea are global nuclear issues -Shifting power in the Economic world -Religious turmoil in the Islamic world -Inspite of these, the world economy steadily growing, driven by: -Technology innovation -Collapse in cost of collecting, analysing & transmitting information -China/India growth -Integration of global market for goods & services - Monetary stability Source: FT, 10 th Jan’2007

Where is the World’s Wealth? Canada 2% Rest of World 10% Japan 27% Germany 4% Italy 4% France 5% UK 6% USA 37% Netherlands 2% Spain 1% Switzerland 1% Taiwan 1% Source: The World Distribution of Household Wealth

Where are the Worlds’ Pharmaceuticals sold? Top 15 countries = 85.9% of worldwide pharmaceutical market estimate % 3.3% 3.4% 4.9% 5.4% 12.0% 44.6% 1.5% 2.0%

A race to prosperity

Global speed of change  The world is changing faster than ever  Globalisation is the key driver of this change  Best hope for the improvement of the lives of the world’s population  Creates wealth  Faster Trade and interdependence  Over the last 2 decade, more people have been lifted out of poverty in Asia than in any other region at any other time in history  Rise of China & India has energised Asia  Education is highly valued in India & Asia

Science Education in EU “This means that when pupils are in a science laboratory their experience is unsafe, unsatisfactory or uninspiring for 65% of the time.” Source: Royal Society of Chemistry, Policy Bulletin – Spring 2006 UK “A” Level entries:Closed UK University % change Chemistry Departments: Physics : 32,059 28, % Dundee Kings Chemistry: 40,856 38,851 -5% Surrey Exeter Maths: 67,036 52, % Lancaster Queen Mary Computing: 19,099 7, % Source: Daily Mail – 11 August 2006 Only pupils at private schools can take physics, chemistry & biology separately Source: Times, 9 th November 2006

Number of Higher Education Institutions 05/06 18, % 00/01 11,412 90/01 5,932 80/01 4,861 Source: Indian University Grants Commission Science Education in India Number of Students enrolled in Higher Education Institutions 05/06 10, % 00/01 7,500 90/01 4,000 80/01 3,000 Source: Indian University Grants Commission Number of Institutions courses 05/06 99/00 Pharmacy % Medicine % Physiotherapy % Source: Pavan Agarwal (2006) based on data from professional councils PhD Degree awarded in Science 03/ % 00/ / (USA 03/04 25,000) Source: Indian University Grants Committee

The Education Advantage Engineers/Science graduates p.a – India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m

The R&D Investment Advantage Most attractive R&D Investment locations: Ranked 3 rd - China, USA, India, Japan & UK Source – UNCTAD 2005 Reasons why India:  Qualified Scientists & Engineers  Global India players with Alliances  English speaking  TRIPs compliant – first patent March 2006  IIT, IIM & other scientific institutions Source – UNCTAD 2005

The Pharma Advantage – API’s USA DMF filings by India Source: Crisil / US FDA / J P Morgan % Share of USA DMF filings India China % 9% % 10% Q1’06 44% 15% Q2’06 41% 16% Q3’06 45% 17% (latest) Source: US FDA / J P Morgan, 6 th August 2006 Source: US FDA, Credit Suisse

- One in every four ANDAs filed by Indian Companies in top USA FDA filers Source: KPMG - No Chinese generic company has yet filed a USA FDA ANDA The Pharma Advantage - ANDAs ANDA Filings in USA by Indian Companies

Global Market Trends for Generic Companies Source: UBS, Businessworld, 30 th October 2006

The Tempest Crystal Ball - Pharma Post TRIPs new pharma products will dry up in India by 2008 Under this pressure Indian Pharma companies will adopt different business models: - Generics, Discovery, Services, M&A MNCs will continue to be attracted to India owing to the science education China will be perceived to be stronger in biology/ toxicology 75% of new R&D sites and 30% of R&D staff globally will be in India/China Alliances between Western Biotech and Indian companies will expand The global generic industry will be dominated by India in the next five years China will dominate the chemical intermediates segment It will be India & China - and not India or China

Our Cultural diversity Country HeadcountNo. of Countries < >10010* Ground operations in 49 countries 1/3 of headcount overall is non Indian * Brazil, Romania, Malaysia, China, Russia, South Africa, Nigeria, Japan US, India

Cultural Diversity is driven by M&A 2003 – 2007 M&A deals in Europe Ranbaxy-6 Stada-2 Matrix-2 DRL-1 Aurobindo-1 Wockhardt-3 Sun Pharma-1 Torrent-1 Jubilant-1 Zydus Cadilla-1 Source: Nomura, 21 st December 2006

Potential for human disconnections Americans-very aggressive - must be clear, start early, finish early Chinese-bargain very aggressively Italians -possessive about their personal time, don’t expect to meet outside office hours & Australiansor weekends Brazilians-love football, fast cars & coffee Canadians-a mixture of Americans and Europeans Scandinavians-don’t appreciate jokes so much Spanish-unusual long lunch hours is the norm French-want to shake hands every morning and may even kiss you Koreans-hardly stop working, but when they do, drink lots of whisky Arabs-a long pre-dinner reception, but the last piece of food ends the meeting Japanese-slow in decision making, very hierarchial, large teams patience needed

Both Japan & India are hungry for Information 1.China123 m 2.Japan 86 m 3.India 51 m 4.S.Korea 34 m Source: Business Today, Sept. 24, China421 m 2.USA190 m 3.Japan157 m 4.Russia148 m 5.India116 m Source: Times of India, Sept. 14, 2006 Internet Usage – Asia Mobile Phones

Japanese – India vs engagement Before timevsAfter time White shirts/ties vs Open neck shirt SashimevsVegetarianism GolfvsCricket Takes time for each side to understand what is a very complex picture, eg. visiting cards, hellos Japanese are heavily influenced by USA, Technology Innovation, Education & Productivity

The Productivity Advantage Indiaa usa Pharma view USA 1 chemist Better education x chemist 70 hours/week Longer working time x hours/week $ 800 monthly Lower cost x 20 $ 12,000 monthly Sources: IPHMR Conferences, New Delhi August 2004

Assessment Centre results on 200 managers  Some brilliant minds with perfect scores  Mathematics are very strong  Great achievers & deliverers of results  Weaker in the softer skills, eg. persuasion & motivation  Team building skills need enhancing  Invest in training

Conclusions  Senior managers need to be chameleons  Management teams should represent a mixture of culture  HR team needs a mixture of cultures  Communications is the most important step  Operate seamlessly in different countries  Sensitive to local culture & traditions  Avoid the expat India clique  Invest in training, transfers, team, travel Source: R.Gopalakrishnan – Asian Management Review, April 2006

Thank You